Proficio Capital Partners LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,282 shares of the specialty pharmaceutical company's stock, valued at approximately $408,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Barclays PLC raised its position in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $791,000. Geode Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after buying an additional 74,438 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after buying an additional 2,121 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $1,498,000.
Supernus Pharmaceuticals Stock Down 1.9 %
SUPN stock traded down $0.62 during trading on Wednesday, hitting $31.40. The company had a trading volume of 652,464 shares, compared to its average volume of 544,818. The firm has a 50-day moving average price of $36.54 and a 200-day moving average price of $35.25. The firm has a market cap of $1.75 billion, a PE ratio of 29.32 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.
Wall Street Analyst Weigh In
Several brokerages have issued reports on SUPN. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
Check Out Our Latest Research Report on SUPN
Insider Transactions at Supernus Pharmaceuticals
In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last 90 days. 9.30% of the stock is currently owned by insiders.
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
